CRDF

Cardiff Oncology, Inc. Common Stock

1.75

USD

CRDF Earnings Reports

Positive Surprise Ratio

CRDF beat 23 of 39 last estimates.

59%

Next Report

Date of Next Report

Feb 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

$96.90K

-$0.19

Implied change from Q3 25 (Revenue/ EPS)

-19.25%

+11.76%

Implied change from Q4 24 (Revenue/ EPS)

-35.83%

-13.64%

Cardiff Oncology, Inc. Common Stock earnings per share and revenue

On Nov 06, 2025, CRDF reported earnings of -0.17 USD per share (EPS) for Q3 25, beating the estimate of -0.20 USD, resulting in a 18.54% surprise. Revenue reached 120.00 thousand, compared to an expected 108.38 thousand, with a 10.73% difference. The market reacted with a -2.67% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 96.90 thousand USD, implying an increase of 11.76% EPS, and decrease of -19.25% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

FAQ

What were Cardiff Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Cardiff Oncology, Inc. Common Stock reported EPS of -$0.17, beating estimates by 18.54%, and revenue of $120.00K, 10.73% above expectations.

How did the market react to Cardiff Oncology, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -2.67%, changed from $2.25 before the earnings release to $2.19 the day after.

When is Cardiff Oncology, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 26, 2026.

What are the forecasts for Cardiff Oncology, Inc. Common Stock's next earnings report?

Based on 11 analysts, Cardiff Oncology, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $96.90K for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.